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Novel Associations in Disorders of Sex Development:
Findings From the I-DSD Registry
Kathryn Cox, Jillian Bryce, Jipu Jiang, Martina Rodie, Richard Sinnott,
Mona Alkhawari, Wiebke Arlt, Laura Audi, Antonio Balsamo, Silvano Bertelloni,
Martine Cools, Feyza Darendeliler, Stenvert Drop, Mona Ellaithi, Tulay Guran,
Olaf Hiort, Paul-Martin Holterhus, Ieuan Hughes, Nils Krone, Lidka Lisa,
Yves Morel, Olle Soder, Peter Wieacker, and S. Faisal Ahmed
Context: The focus of care in disorders of sex development (DSD) is often directed to issues related to
sex and gender development. In addition, the molecular etiology remains unclear in the majority of
cases.
Objective: To report the range of associated conditions identified in the international DSD (I-DSD)
Registry.
Design, Setting, and Patients: Anonymized data were extracted from the I-DSD Registry for di-
agnosis, karyotype, sex of rearing, genetic investigations, and associated anomalies. If necessary,
clarification was sought from the reporting clinician.
Results: Of 649 accessible cases, associated conditions occurred in 168 (26%); 103 (61%) cases
had one condition, 31 (18%) had two conditions, 20 (12%) had three conditions, and 14 (8%)
had four or more conditions. Karyotypes with most frequently reported associations included
45,X with 6 of 8 affected cases (75%), 45,X/46,XY with 19 of 42 cases (45%), 46,XY with 112 of
460 cases (24%), and 46,XX with 27 of 121 cases (22%). In the 112 cases of 46,XY DSD, the
commonest conditions included small for gestational age in 26 (23%), cardiac anomalies in 22
(20%), and central nervous system disorders in 22 (20%), whereas in the 27 cases of 46,XX DSD,
skeletal and renal anomalies were commonest at 12 (44%) and 8 (30%), respectively. Of 170
cases of suspected androgen insensitivity syndrome, 19 (11%) had reported anomalies and 9
of these had confirmed androgen receptor mutations.
Conclusions: Over a quarter of the cases in the I-DSD Registry have an additional condition.
These associations can direct investigators toward novel genetic etiology and also highlight the
need for more holistic care of the affected person. (J Clin Endocrinol Metab 99: E348–E355,
2014)
Disorders of sexdevelopment (DSD) are a groupof rareconditions that usually present in early infancywith
an abnormality of the external and/or internal reproduc-
tive organs and commonly arise because of a disorder of
gonadal, adrenal, or hormonal function. Although the
overall birth prevalence of conditions associated with
DSD may be as high as 1 in 300 (1), individual patho-
physiological conditions aremuch rarer, limiting the study
of their etiology and prognosis.
Although enormous advances in our knowledge have
been achieved over the last decade, the genetic etiology in
most cases of DSD remains unclear (2, 3). Furthermore,
our understanding of the basis of the genetic modifiers of
monogenic DSD remains in its infancy. Mammalian sex
development, which is already known to be closely linked
to the development of the urological system (4), occurs at
critical stages of embryonic and fetal development. These
windows may also be important for the development of
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other organs as illustrated by a number of known condi-
tions associated with DSD (5–7). High-throughput gene
sequencing technology has the potential to identify a num-
ber of attributable genetic variations but understanding
the linkbetween these variations and the clinical condition
may prove to be a challenge. An improved knowledge of
the range of associated conditions that exist in peoplewith
DSD not only will help with interpreting the results of the
genetic analyses but also will aid with the management of
the affected patient.
Although a link between DSD and associated anoma-
lies is recognized (1), it is generally thought that conditions
such as hypospadias are rarely associated with abnormal-
ities beyond the genitourinary system (8). Given the rarity
ofDSD, it has been difficult to ascertain the frequency and
nature of associated anomalies in these cases. The Con-
sensus Guidelines on DSD published in 2006 stressed the
need for the creation and maintenance of a database in
centers of expertise (9). Such databases do exist in many
regional and national centers and have provided valuable
insights into many aspects of DSD, including epidemiol-
ogy (1), etiology (10, 11), variation of disease expression
(12), initial adjustment of parents to their affected child’s
condition (13), and long-term outcome (14). However, as
these databases and registries lacked uniformity, an inter-
national DSD (I-DSD) registry that collects information
on cases with a range of conditions has now been in op-
eration to overcome these issues (15). We have used this
model of international collaboration to report on the larg-
est cohort of cases of DSD that has been studied for as-
sociated anomalies.
Subjects and Methods
Details of the I-DSD Registry, including its development and
current operation, have been previously reported (15, 16) and
are also available from its web site (www.i-dsd.org). Briefly,
all clinicians belonging to recognized professional medical
and scientific societies are eligible to register and report cases.
This information is required when the clinician first registers
as a user of the Registry. Users are then approved by the
steering committee of the Registry before they can submit any
cases. There are no restrictions on the age requirement of the
case, with the Registry serving both adult and pediatric pop-
ulations, and there is no time limit between initial presentation
or diagnosis and entry into the Registry. Patient and/or pa-
rental consent must be obtained before case registration, with
the level of consent tiered according to the extent to which the
information may be shared (own center, own country, Euro-
pean Union member states, international). The I-DSD Regis-
try is approved by the National Research Ethics Service of the
United Kingdom.
The terminology used within the Registry is based on the
nomenclature initially developed at theChicago consensusmeet-
ing and which has continued to evolve subsequently (9, 15). In
addition to details of diagnosis, the I-DSD Registry collects sim-
ple information on physical conditions that affect systems other
than the reproductive system, as well as the occurrence of con-
ditions such as small for gestational age (SGA), and short stature.
See Supplemental Tables 1–4, published on The Endocrine So-
ciety’s Journals Online web site at http://jcem.endojournals.
org, for details of the data fields in the Registry.
At the time of the study in September 2012, there were 1050
cases submitted by registered clinicians from 20 centers in 14
different countries. Reporting clinicians for cases represented a
range of specialties, including pediatric endocrinology, adult en-
docrinology, clinical genetics and biochemistry, and their coun-
tries of origin, are outlined in Supplemental Table 5. On ana-
lyzing the extracted data, 649 (62%) cases had a sufficient level
of consent to allow sharing of suitable information.Anonymized
data were obtained from the Registry regarding diagnosis,
karyotype, sex of rearing, clinical center, genetic investigations,
and any associated anomalies. Until September 2012, the field
that captures “associated conditions”was labeled as “associated
malformations.”The field does not seek any further information
on whether the associated condition is early onset, late onset, or
acquired. Short stature in congenital adrenal hyperplasia was
excluded from the analysis because this is a condition that is
acquired as a consequence of the management of the disorder.
Furthermore, the data were subanalyzed with the exclusion of
caseswhere the conditionwas known to be associatedwith specific
anomalies, namely P450 oxidoreductase deficiency (PORD),Mül-
lerian duct aplasia, renal dysplasia, and cervical somite anomalies
(MURCS), Mayer-Rokitansky-Küster-Hauser syndrome (MRKH),
Turner syndrome, and 45,X/46,XY.Where informationwas unclear
or incomplete, the reporting clinicianwas contacted to obtain further
information.
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Results
Karyotype
Of the 649 cases analyzed, 460 (71%), were 46,XY,
121 (19%) were 46,XX, 42 (6%) were 45,X/46,XY, 8
(1%) were 45,X, 6 (1%) were 46,XX/46,XY, 2 (0.3%)
were 47,XXY, with other atypical karyotypes (such as
translocations) making up the remaining 10 cases (1%).
Of these cases with the respective karyotypes, associated
conditions were reported in 6 cases of 45,X (75%), 19
cases of 45,X/46,XY (45%), 112 cases of 46,XY DSD
(24%), 27 cases of 46,XX DSD (22%), and 4 cases with
the atypical karyotypes (22%). Disorders of gonadal de-
velopment occur in patients with a variety of karyotypes,
and in the current cohort, of the 63 cases of a disorder of
gonadal development with an associated condition, 33
(52%) were 46,XY, 3 (5%) were 46,XX, 5 (8%) were
45,X, 19 (30%) were 45,X/46,XY, 1 (2%) was 47,XXY,
and 2 (2%) had an atypical karyotype.
Multiple conditions
Of the 649 cases, associated conditions occurred in 168
(26%). Of these 168 cases, 103 (61%) cases had one con-
dition each, 31 (18%) had two conditions, 20 (12%) had
three conditions, and 14 (8%) had four or more condi-
tions, with the maximum number being eight. Multiple
conditions (more than one per case) were reported in 3 of
6 (50%) cases of 46,XX disorders of Müllerian develop-
ment, 22 of 44 (50%) cases of nonspecific 46,XYDSD, 25
of 63 (40%) cases of disorders of gonadal development, 7
of 19 (37%) cases of disorders of androgen action, 3 of 11
(27%) cases of disorders of androgen excess, and 2 of 18
(11%) cases of disorders of androgen synthesis. Further de-
tails of the conditions encountered are outlined in Table 1.
Range of conditions
The range anddistributionof associated conditions dif-
fered substantially between cases of 46,XY and 46,XX
DSD (Figure 1). SGA was reported in 26 of 112 cases
(23%) of 46,XY DSD with associated conditions; how-
ever, therewere no cases of SGA in the 46,XXDSDgroup.
Central nervous system (CNS) and cardiac conditions
were next most frequent in 46,XY DSD, each reported in
22 of the 112 cases (20%) of 46,XY DSDwith associated
conditions.
In the 90 cases of nonspecific XY DSD without any
clear diagnosis on the registry, 17 (19%) were reported to
be SGA, 11 (12%) had cardiac abnormalities, and 8 (9%)
had involvement of the CNS (Table 1). In the 153 cases of
Table 1. Reported Anomalies According to Disorder Classification
Number of Cases With Each Type of Anomaly
Disorder Type
(number of
accessible
cases in
Registry)
Number
of Cases
With
Anomaly Adrenal
Blood
and
Lymph CNS Craniofacial ENT Eyes
GI
Tract Heart Renal Respiratory SGA
Short
Stature Skeletal Skin
Undefined
Syndrome Other
Number
of Cases
With
Anomaly
by
Karyotype
Gonadal
development
(153)
63 1 3 9 9 7 4 4 14 17 4 5 19 7 - 3 6 46,XY-–33
46,XX-–3
45,X-–5
45,X/46,
XY-–19
47,XXY-–1
Other-–2
Androgen
synthesis
(100)
18 - - 1 1 - - - - - - 1 - 13 1 - 3 46,XY-–9
46,XX-–9
Androgen
action (172)
19 - - 3 1 - 2 2 3 3 2 5 4 3 1 1 7 46,XY-–19
Androgen
excess (75)
9 - - 1 1 - - 1 1 2 - - - 1 - 1 5 46,XY-–1
46,XX-–8
Nonspecific
XY DSD (90)
44 1 1 8 4 5 3 6 11 7 3 17 4 5 3 1 10 46,XY-–44
XX Müllerian
devpt (12)
6 - - 1 - - 1 - 1 6 - - - 2 - 1 - 46,XX-–6
PMDS (5) 1 - - - - - - - - - - - - - - - 1 46,XY-–1
Leydig cell
defects (17)
1 - - 1 1 - 1 - - - - - - 1 1 - - 46,XY-–1
Other (25) 7 1 - 3 - - - - 2 - - - 1 - - 1 1 46,XY-–5
46,XX-–1
45,X-–1
Total (649) 168 3 4 27 17 12 11 13 32 35 9 28 28 32 6 8 33
Abbreviation: PMDS, persistent Müllerian duct syndrome. Dashes indicate no cases recorded.
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disorders of gonadal development on the registry, 19
(12%) had short stature (15 of which occurred in cases
with 45,X or 45,X/46,XY karyotype, 3 in cases of 46,XY
DSD, and 1 case with an atypical karyotype), 17 (11%)
had renal anomalies (7 of which occurred in cases with
45,Xor 45,X/46,XYkaryotype), and14 (9%)had cardiac
abnormalities (6 of which occurred in cases with 45,X or
45,X/46,XY karyotype) (Table 1).
Conditions affecting the skeleton were present in 12 of
27 (44%) cases of 46,XX DSD with an associated condi-
tion and these cases included two cases of MURCS, diag-
nosed clinically, seven cases of PORDallwith genetic con-
firmation of diagnosis, two unconfirmed nonclassical 3-
hydroxysteroid dehydrogenase deficiency, andone case of
11-hydroxylase deficiency, with genetic confirmation.
Conditions involving renal development were encoun-
tered in 8 of the 27 cases (30%) and were commonest in
those with a 46,XX disorder of Müllerian development,
occurring in 6 of 12 cases in the Registry (50%), and pres-
ent in all such cases that had an anomaly recorded.
As associated conditions are already known to occur in
some syndromes associated with DSD, 8 cases of Turner
syndrome, 42 cases of 45,X/46,XY, 19 cases of PORD,
and 12 cases of Müllerian development anomalies were
excluded from the overall 649 cases.Of the remaining 568
cases, 127 (22%) had an associated condition that did not
form a recognized part of the disorder. Of these 127, 108
(85%) were 46,XY, 15 (12%) were 46,XX, 2 (2%) had a
nonsex chromosome rearrangement, and there was 1 case
each (1%)of 46,XX/46,XYand47,XXY, respectively.Of
these 127 cases, 75 (60%) had one condition, 22 (17%)
had two conditions, 18 (14%) had three conditions, and
12 (9%) had four or more conditions, with the maximum
number of conditions encountered in one patient being
eight. Among these 127 cases there were 44 cases of non-
specific 46,XY DSD, 39 cases of disorders of gonadal de-
velopment, 19 cases of disorders of androgen action, 10
case of disorders of androgen synthesis, 9 cases of disor-
ders of androgen excess, 1 case each of Leydig cell defects
and persistentMüllerian duct syndrome, and 6 cases clas-
sified as “other” disorders. Of the 39 cases of disorders of
gonadal development, 10 (26%) had a renal condition, 8
(21%) had a cardiac condition, 8 (21%) had a CNS con-
dition, 8 (21%) had a craniofacial disorder, 4 each (10%)
had short stature, ear, nose, and throat, gastrointestinal
(GI) tract, respiratory or skeletal conditions, 3 (8%) had
blood and lymph conditions, eye conditions, SGA, or an
unidentified syndrome, and 1 (3%) had an adrenal
condition.
The pattern and frequency of anomalies also varied
between 46,XY and 46,XX DSD after exclusion of the
syndromic DSD conditions (Figure 2). Of the 451 cases of
46,XYDSD, an associated condition was reported in 108
(24%) and in 15 of 98 cases (15%) of 46,XX DSD. In
46,XY DSD, SGA was the most frequent condition in 26
cases (24%), with cardiac anomalies in 22 cases (20%)
and CNS conditions in 21 cases (19%). In 46,XX DSD,
there was an even spread of conditions with the most fre-
quent condition being skeletal occurring in 3 of 15 cases
(20%).
Monogenic DSD
Of 170 cases reported as androgen insensitivity syn-
drome (AIS), 19 (11%) were recorded as having an asso-
ciated condition. Of these 19 cases, 9 had a confirmed
androgen receptor mutation, occurring in six cases of
Complete AIS and three cases of Partial AIS. Associated
conditions were reported to affect the renal system in two
cases, skeleton in one case, skin in one case, CNS in one
case, GI tract in one case, heart in one case, and an un-
specified condition in five cases (Table 2). Associated con-
ditions were also reported in 8 of 72 (11%) cases of 21-
hydroxylase deficiency (1 of which had confirmed
CYP21A2mutation, while the remainder were diagnosed
clinically), 4 of 26 (15%) cases of 17-hydroxysteroid
dehydrogenase type 3 deficiency (all with confirmed
Figure 1. Range of anomalies reported in 46,XX and 46,XY DSD.
Figure 2. Range of anomalies reported after exclusion of known DSD
syndromic associations in 46,XX and 46,XY DSD.
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HSD17B3 mutation), and 2 of 19 cases (10%) of 5-re-
ductase type 2 deficiency. In the 8 cases of 21-hydroxy-
lase deficiency, two had renal conditions. In the remain-
der, there was one case of a CNS condition, one affecting
the GI tract, and one case each detailed as severe autism,
spastic paraplegia, polyarthritis, learning disability, and
one not specified.
Discussion
The results from this analysis of the I-DSDRegistry reveal
that associated conditions are frequent inDSD,with a rate
of 27%, which is over 10 times the birth prevalence of
congenital anomalies (17). This is not unexpected, given
that the presence of one congenital condition is known to
be associated with the presence of further anomalies be-
cause disrupting factors, whether environmental or ge-
netic, are likely to affect multiple developmental pro-
cesses. Furthermore, approximately 10% of the cases of
DSD had more than one associated condition, highlight-
ing the need for input from multiple specialists. When
cases with DSD syndromes and chromosomal anomalies
were excluded, the overall frequency of associated condi-
tions was similar to the overall cohort. These figures are
also in keeping with the findings of an epidemiological
study carried out in Germany that identified a higher rate
of 37.5% for associated malformations in infants with
ambiguous genitalia (18).
Although the ranges of anomalies that are encountered
are different, it is of interest that in the current cohort of
cases in the I-DSD Registry, the reported prevalence of
associated conditions in 46,XY and 46,XX DSD at 24%
and 22%was similar. With the exclusion of the cases that
are well known to be associated with anomalies, the prev-
alence of associated conditions in the other cases of 46,XY
and 46,XX DSD was 24% and 15%, respectively. The
type of conditions encountered in 45,X/46,XY cases bears
a striking resemblance to the known phenotype in Turner
syndrome, with partial or complete gonadal dysgenesis.
This is reflected in the high frequency of associated con-
ditions in all cases with gonadal dysgenesis. Our findings
echo the description of the 45,X/46,XY phenotype by
Tosson et al and Telvi et al (19, 20) and the cardiac phe-
notype refined by De Groote et al (21). These findings
highlight the importance of a thorough screening for as-
sociated conditions in both male and female individuals
with this karyotype.
It has long been recognized that there is a strong
association between SGA and DSD (1, 22), and this was
reflected in our findings. It was notable that there were
no reported cases of SGA in 46,XX DSD. It has been
speculated that altered prenatal androgen exposure
may alter in utero growth but this is debatable (23, 24).
An alternative hypothesis for the origins of low birth
weight in 46,XY DSD is that both are the result of early
placental insufficiency (25, 26) and this requires further
investigation.
Table 2. Reported Anomalies in Monogenic Conditions
Number of Cases With Each Anomaly
Disorder
Total
Number
Number
Cases
With
Anomaly CNS Craniofacial Eyes
GI
Tract Heart Renal Respiratory SGA
Short
Stature Skeletal Skin
Undefined
Syndrome Other
Disorders of androgen synthesis
17hydroxysteroid dehydrogenase
type 3 deficiency
26 4 1 - - - - - - - - 1 - - 3
5 reductase type 2 deficiency 19 2 - - - - - - - 1 - - 1 - -
P450 oxidoreductase deficiency 19 10 - 1 - - - - - - - 10 - - -
Disorder of androgen action
Complete androgen insensitivity
syndrome (AR mutation ve)
77 6 1 - - 1 1 1 - - - - 1 - 3
Complete androgen insensitivity
syndrome (AR mutation ve/
unknown)
16 3 - - - - - 1 - - - 1 - - 1
Partial androgen insensitivity
syndrome (AR mutation ve)
39 3 - - - - - 1 - - - 1 - - 2
Partial androgen insensitivity
syndrome (AR mutation ve)
38 7 2 1 2 1 2 - 2 5 4 1 - 1 1
Disorder of androgen excess
21Hydroxylase deficiency 72 8 1 - - 1 1 2 - - - - - - 5
11Hydroxysteroid dehydrogenase
deficiency
1 1 - 1 - - - - - - - 1 - 1 -
Abbreviation: AR, androgen receptor. Two cases reported as possible nonclassic 3-hydroxysteroid dehydrogenase have been included in Table 1
as androgen synthesis disorders, but due to diagnostic uncertainty have not been included in the monogenic conditions in Table 2. Two cases
described as “disorders of androgen excess” have the diagnosis “other” with no confirmed diagnosis and are therefore not included in Table 2.
Dashes indicate no cases recorded.
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In 46,XXDSD, an associationwith skeletal and renal
anomalies is recognized in conditions such as MURCS,
MRKH, and PORD (7, 27). This was borne out by our
results, in which renal conditions were common in
women with 46,XX DSD and disorders of Müllerian
development. Similarly, skeletal involvement was also
observed in women with 46,XX DSD and PORD or
MURCS. Renal disorders are also a recognized feature
of 46,XY DSD due to the Denys Drash and WAGR
(Wilms, Aniridia, Genitourinary anomalies, mental Re-
tardation) syndromes. Furthermore, bone and kidney
abnormalities combined with genital anomalies are a
component of Smith-Lemli-Opitz syndrome (28). Renal
tract anomalies have previously been reported as oc-
curring in 14 of 66 females (21%) with congenital ad-
renal hyperplasia (29) and were also confirmed to be
present in the current cohort occurring in two cases of
21-hydroxylase deficiency. When recognized associa-
tionswere excluded from the analysis, renal and skeletal
disorders were still encountered in up to 4% of cases of
46,XX DSD and 46,XY DSD.
The unexpected presence of renal abnormalities in
AIS cases with a confirmed androgen receptor mutation
raises a question about the developmental role of the
androgen receptor in the kidney. Previously, an associ-
ation between Complete AIS and renal anomalies has
been described in one case (30). In mice, the kidney is
one of the most androgen sensitive, nonreproductive
organs, with a close correlation between kidney mass
and androgen levels in themale (31). In addition, several
developmental genes are known to be androgen-regu-
lated in the mouse (32). Our finding of two cases with
renal anomalies in congenital adrenal hyperplasia is
also worthy of emphasis, as it highlights the importance
of thorough investigation of the whole renal tract in
such patients. Ten cases reported as AIS without a con-
firmed androgen receptor mutation had an associated
condition. Of these, five cases had SGA and four had
short stature. Given that these associations are often
encountered in cases of gonadal dysgenesis, these cases
of presumed AIS need a thorough investigation of go-
nadal function.
It is possible that some of the associations revealed by
our analysis of the Registry may represent co-occur-
rence of anomalies by chance. Renal tract anomalies
have been reported as occurring with a frequency of 25
per 1000 in the general European population (17). This
compares to a frequency in our analysis of 35 of 649,
equivalent to 54 per 1000. The frequency of cardiac
anomalies, the second most common anomaly in our
population, is reported as 8 per 1000 in the European
population (33). This compares to the occurrence of
cardiac anomalies in our analysis of 32 of 649, equiv-
alent to 49 per 1000.
The I-DSDRegistry is not an epidemiological registry
and, as it does not collect information on all cases of
DSD, it may suffer from a reporting and selection bias.
It is recognized that there may be a bias toward the
reporting of more clinically unusual cases, which could
increase the reported prevalence of anomalies. Registry
users can also choose the extent of data sharing with
other users for each individual case and this sharingmay
depend on the patient’s or clinician’s preference. Based
on the access level of the investigators, only 60% of the
cases in the Registry could be accessed for this study and
this may have also introduced some selection bias.
However, the similarities between our results and the
findings of a national study suggest that the prevalence
figure of 25% for associated conditions probably is rep-
resentative of the true prevalence (18). In particular,
cases of congenital adrenal hyperplasia may be under-
represented in the Registry due to reporting methods,
given that the incidence in the general population is
estimated at around 1 in 15 000 live births (34). The
incidence of AIS was described in a Danish population
registry as 1 in 20 400 (35), whereas MRKH is esti-
mated as occurring in 1 in 4500 females (36). However,
the Registry does not necessarily represent the popula-
tion prevalence of these disorders because it relies on
clinician reporting rather that population screening.
All data are self-recorded by the clinician, with little
recourse to source verification of entered data, and it
can be difficult in such a registry to be clear that all users
have the same understanding of an associated condition
that is congenital. It is also possible that some congen-
ital conditions may not be manifested until a later age.
Until recently, the data collection form asked investi-
gators to enter data on “associated malformations,”
which implies congenital conditions.More recently, the
term “malformations” has been replaced by the term
“conditions.” It would be beneficial in future revisions
of the Registry to provide some explanatory data to
ensure that conditions that are considered to be of con-
genital and those considered to be acquired are captured
separately and there may be additional value in assess-
ing the age of onset of the manifestation of the
condition.
However, the use of an international registry of such
rare conditions in such a large group of cases has, nev-
ertheless, pointed to some new associations in DSD and
the study highlights the strength of a global effort to
collect data in rare diseases, which will encourage re-
porting of more cases of DSD with associated condi-
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tions. In conclusion, we have found that, in this cohort
of cases, associated anomalies are reported in around a
quarter of cases of DSD. The prevalence of associated
conditions is much greater in disorders of gonadal de-
velopment and nonspecific 46,XYDSD. In 46,XYDSD,
the largest group of cases in the Registry, the common-
est associated conditions included SGA, cardiac, and
CNS. In many cases of DSD the etiology remains ob-
scure and the current findings may lead to new research
targets as well as improved care of those affected by
these disorders.
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